CTLA-4 is one of the immune system's most critical brakes — a checkpoint receptor expressed on activated T cells that prevents them from attacking the body's own tissues. While much attention has focused on coding and 3'UTR variants in CTLA4, the far-upstream regulatory landscape also influences how much CTLA-4 the immune system produces. The MH30 variant (rs231806), located approximately 23 kilobases upstream of the CTLA4 coding sequence, sits within a long-range regulatory element¹¹ regulatory element
Distal regulatory elements can loop physically to gene promoters and modulate transcription factor access across tens of kilobases that influences CTLA4 gene expression. This variant has been specifically implicated in latent autoimmune diabetes in adults (LADA) — a slowly progressing form of autoimmune diabetes that is frequently misdiagnosed as type 2 diabetes at onset.

The Mechanism

The MH30 region lies within a chromatin-accessible, distal regulatory domain upstream of CTLA4. Regulatory variants at this distance can influence transcription factor binding and long-range chromatin looping that brings upstream elements into contact with the gene's core promoter. The G allele at rs231806 is the population-major allele globally (~60% frequency) and is part of a disease-associated haplotype (GCC — combining the G allele at MH30 with specific alleles at the -1147 position (rs16840252) and -318 position (rs5742909)²² -1147 position (rs16840252) and -318 position (rs5742909)
These three promoter-region SNPs were studied together in the Estonian LADA cohort as part of CTLA4 haplotype analysis).

The functional consequence appears to be reduced production of the soluble isoform of CTLA-4 (sCTLA-4)³³ soluble isoform of CTLA-4 (sCTLA-4)
Soluble CTLA-4 is secreted into the extracellular space and acts as a decoy receptor that blocks B7 costimulatory ligands, suppressing T cell activation independently of cell surface CTLA-4. In a study of newly diagnosed type 1 diabetes patients, sCTLA4 mRNA expression was significantly lower in individuals homozygous for the G allele (GG genotype, p=0.039). Less soluble CTLA-4 means a less effective extracellular dampening signal on T cell activation — potentially lowering the threshold for autoreactive T cells to escape regulation and attack pancreatic beta cells.

The Evidence

The primary association between rs231806 and LADA comes from a study of 61 LADA patients and 230 controls⁴⁴ study of 61 LADA patients and 230 controls
Douroudis, Prans, and Uibo, Human Immunology, 2009 in an Estonian population. The MH30 GG genotype was significantly more frequent in LADA patients (p=0.0051), and the G allele was overrepresented among cases (p=0.0023). Haplotype analysis reinforced the finding: the GCC haplotype (spanning rs231806, rs16840252, and rs5742909) was significantly elevated in LADA cases (p=0.000073), while the CCC haplotype was protective (p=0.0019).

A follow-up population study comparing LADA, T1D, T2D, and controls⁵⁵ follow-up population study comparing LADA, T1D, T2D, and controls
Kisand and Uibo, Gene, 2012; 65 LADA, 154 T1D, 260 T2D, 229 controls found that LADA had a distinct genetic risk profile from classical T1D: LADA was associated with protective HLA haplotypes and with CTLA4 haplotypes (including rs231806) rather than the classical T1D HLA risk alleles. A model using CTLA4 region and HLA-DQB1 predicted LADA with AUC 0.693, confirming the CTLA4 region as a genuine LADA susceptibility locus.

Expression data from a study of B7/CD28 family genes in 49 newly diagnosed T1D children⁶⁶ study of B7/CD28 family genes in 49 newly diagnosed T1D children
Pruul et al., Human Immunology, 2013 showed that sCTLA4 mRNA was lowest in GG individuals at rs231806 (p=0.039), providing a mechanistic link between genotype and reduced immune regulation.

Importantly, the -318C/T (rs5742909) and -1147 (rs16840252) SNPs studied alongside rs231806 in the same Estonian LADA cohort showed no individual associations — only the MH30 (rs231806) G allele reached significance on its own, while the three-SNP GCC haplotype provided the strongest combined signal.

The evidence level is emerging — the LADA association comes from a single case-control study with a small sample (n=61 LADA). This is a real and biologically plausible signal with mechanistic support, but independent replication in larger cohorts is needed to confirm the effect size and establish the risk quantitatively.

Practical Implications

The GG genotype is the most common globally (~36% of people) but carries the highest MH30-associated LADA risk. LADA is frequently misdiagnosed as type 2 diabetes at onset because patients are often adults and not immediately insulin-dependent — but unlike T2D, LADA involves progressive beta cell destruction by autoreactive T cells, requiring insulin therapy within a few years. Awareness of CTLA4 risk genotypes may support earlier antibody testing (GAD65, IA-2) in adults presenting with apparent type 2 diabetes who don't respond well to oral agents.

For individuals who already have LADA or are being evaluated for possible LADA, CTLA4 genotype is one of several risk markers alongside islet autoantibodies, HLA type, and clinical presentation. No CTLA4-genotype-based intervention currently alters LADA management, but abatacept (a CTLA-4-Ig fusion protein)⁷⁷ abatacept (a CTLA-4-Ig fusion protein)
Abatacept mimics CTLA-4 function and is being studied in preserving beta cell function in early autoimmune diabetes is under investigation as a beta cell-preserving agent in early T1D and LADA.

Interactions

rs231806 is part of a three-SNP CTLA4 haplotype studied together with rs16840252 (-1147) and rs5742909 (-318C/T). The GCC haplotype combining risk alleles across all three upstream variants showed the strongest LADA signal (p=0.000073), much stronger than any single variant alone. This suggests epistatic cooperation within the upstream CTLA4 regulatory architecture.

The other two established CTLA4 variants — rs3087243 (CT60, 3'UTR) and rs231775 (+49A/G, coding) — provide complementary and stronger associations with autoimmune thyroid disease, T1D, and rheumatoid arthritis. Together, rs231806 + rs3087243 + rs231775 form a fuller picture of CTLA4 autoimmune susceptibility spanning promoter, coding, and 3'UTR regions. LADA risk is particularly sensitive to the upstream regulatory haplotype (rs231806), while thyroid and rheumatoid disease are more strongly predicted by the downstream variants.

The CBS gene encodes [cystathionine beta-synthase | the enzyme that commits homocysteine to the transsulfuration pathway, converting it to cystathionine, then cysteine, then glutathione], a vitamin B6-dependent enzyme located on chromosome 21. CBS sits at the critical junction where the methylation and transsulfuration pathways diverge: it irreversibly diverts homocysteine away from the methylation cycle and toward cysteine and [glutathione | the body's most abundant antioxidant, synthesized from cysteine via glutamate and glycine] synthesis. rs234709 is an intronic variant within CBS — it does not change the protein sequence, but it tags the CBS locus in population genetics studies and captures variation in CBS expression and enzyme activity across the haplotype block.

The Mechanism

rs234709 sits in intron 5 of the CBS gene on the minus strand of chromosome 21 (GRCh38 position chr21:43,066,854, C>T on the plus strand). As an intronic variant, it does not directly alter the CBS protein. However, [intronic variants in regulatory introns can influence mRNA splicing, stability, or transcription factor binding | affecting how much protein is produced, not its sequence], and rs234709 is in [linkage disequilibrium | LD; the tendency of nearby genetic variants to be inherited together as a haplotype block] with the functional CBS C699T variant (rs234706, r²=0.69). This means the T allele at rs234709 predominantly co-occurs with the common C allele of CBS C699T — the haplotype associated with lower CBS enzyme efficiency — rather than with the protective T allele of C699T. CBS requires [pyridoxal-5-phosphate (PLP) | the active form of vitamin B6] as an essential cofactor and is allosterically activated by [S-adenosylmethionine (SAMe) | the universal methyl donor in the cell, linking CBS activity to methionine availability]. When CBS activity is reduced, homocysteine accumulates in plasma and tissues. Elevated homocysteine impairs nitric oxide synthase activity, promotes oxidative stress, and increases cardiovascular and neurological risk. The enzyme also generates [hydrogen sulfide (H₂S) | a gaseous signaling molecule with vasodilatory, cytoprotective, and anti-inflammatory properties] as a byproduct of CBS-catalyzed reactions. Variants in CBS affecting enzyme expression thus have downstream effects not just on homocysteine clearance and glutathione synthesis, but also on H₂S production — a connection explored in sepsis research.

The Evidence

The strongest evidence for rs234709 comes from a study of 142 arsenic-exposed individuals in Argentina¹¹ 142 arsenic-exposed individuals in Argentina
Porter et al., Environmental Research, 2010. The T allele was associated with a 24% increase in monomethylarsonic acid (%MMA) excretion (from 14.4% to 18.8%), alongside a 7% decrease in dimethylarsenic. This finding is mechanistically informative: arsenic methylation is driven by the same one-carbon pool (SAMe) that CBS competes with, and reduced CBS efficiency is expected to impair the SAMe-dependent methylation of arsenic. The T allele association with worse arsenic methylation is consistent with the T allele tagging a reduced-activity CBS haplotype. A 2014 GWAS meta-analysis²² 2014 GWAS meta-analysis
Williams et al., PLOS Genetics, 2014 of homocysteine and methionine metabolism in large European cohorts identified the CBS locus — including rs234709 — as one of five major genetic determinants of plasma homocysteine concentrations. CBS polymorphisms collectively explained a portion of the homocysteine variance at genome-wide significance (p = 3.15×10⁻²⁶). A Mendelian randomization analysis³³ Mendelian randomization analysis using 13 homocysteine-associated loci (including CBS) found that genetically elevated homocysteine was NOT associated with coronary artery disease risk in white populations, refuting the causal relevance of moderately elevated homocysteine despite its established observational correlation with CVD. A Chinese sib-pair study⁴⁴ Chinese sib-pair study
Sun et al., Journal of Thrombosis and Thrombolysis, 2017 examined CBS rs2851391 (in the same CBS locus as rs234709) alongside other one-carbon metabolism SNPs in relation to carotid intima-media thickness (CIMT), a measure of subclinical atherosclerosis. The CBS locus showed associations with CIMT through interaction effects with other one-carbon metabolism genes. A European study identified CBS gene variants as associated with susceptibility to sepsis⁵⁵ susceptibility to sepsis
Sponholz et al., European Journal of Human Genetics, 2016, linking CBS-dependent H₂S production to sepsis susceptibility — a distinct mechanism from homocysteine that highlights the breadth of CBS's physiological role.

Practical Actions

The T allele at rs234709 tags a haplotype background associated with lower CBS enzyme efficiency. In practical terms, this means a modestly reduced capacity to: (1) clear homocysteine via transsulfuration, (2) produce cysteine for glutathione synthesis, and (3) generate cytoprotective H₂S. These effects are subtle compared to pathogenic CBS mutations that cause homocystinuria, but they are relevant when combined with other methylation pathway variants (particularly MTHFR) or when dietary B vitamin status is marginal. The primary intervention is ensuring optimal cofactor availability. CBS is directly dependent on vitamin B6 (as PLP), and the broader methylation cycle requires folate and B12. Using the active forms of these vitamins — methylfolate (5-MTHF) rather than folic acid, methylcobalamin rather than cyanocobalamin, and P5P rather than pyridoxine — bypasses enzymatic conversion steps that may be impaired by other genetic variants.

Interactions

rs234709 is in linkage disequilibrium with rs234706 (CBS C699T, r²=0.69) — the two variants are co-inherited as part of the CBS haplotype block. Because they are not in perfect LD, however, they capture partially overlapping but distinct variation, and both are included in our database to capture the full CBS locus. The most clinically important interaction is with MTHFR (rs1801133 C677T and rs1801131 A1298C). Reduced MTHFR activity causes homocysteine accumulation upstream, and when CBS efficiency is also reduced (as suggested by the T allele at rs234709), there is less capacity to reroute the excess homocysteine through transsulfuration. This double impairment — reduced remethylation and reduced transsulfuration — can meaningfully elevate plasma homocysteine and increase cardiovascular risk. Individuals carrying both MTHFR risk alleles and the CBS rs234709 T allele should prioritize measuring plasma homocysteine and ensuring all methylation cofactors are optimal.

Uterine fibroids (leiomyomas) are benign tumors of the uterine smooth muscle that affect up to 70–80% of women by age 50, though only about 20–25% experience significant symptoms. They are the most common benign gynecological tumor globally and the leading indication for hysterectomy. While most fibroids are managed conservatively or with minimally invasive procedures, they cause heavy menstrual bleeding, pelvic pain, and — in some locations — fertility complications.

The rs2456181 variant sits in an intron of ZNF346 (zinc finger protein 346, also known as JAZ) on chromosome 5q35.2. It was identified as a genome-wide significant fibroid susceptibility locus in a landmark 2018 GWAS by Välimäki et al.¹¹ landmark 2018 GWAS by Välimäki et al.
15,453 uterine leiomyoma cases and 392,628 controls from UK Biobank and Finnish cohorts. The risk (G) allele carries an odds ratio of 1.07 (p=6.3×10⁻⁹), a modest individual effect that is consistent with the polygenic architecture of fibroid susceptibility.

ZNF346 encodes a nucleolar zinc finger protein that preferentially binds double-stranded RNA and RNA/DNA hybrids. It shuttles between nucleus and cytoplasm via a complex with exportin-5 (XPO5) and ILF3, and plays a role in regulating cell cycle entry and apoptosis. Despite giving the locus its name, ZNF346 itself may not be the primary causal gene at this position.

The functional story points instead to FGFR4 (fibroblast growth factor receptor 4)²² FGFR4 (fibroblast growth factor receptor 4)
A nearby gene encoding a cell-surface receptor that drives cell proliferation, differentiation, and survival, which lies approximately 200 kb from rs2456181 at the same 5q35.2 locus. Transcriptomic analyses of this GWAS signal show that the G risk allele acts as a cis-eQTL³³ cis-eQTL
A regulatory variant that alters expression of nearby genes in the same chromosomal region: it increases FGFR4 expression in blood, arteries, subcutaneous adipose tissue, and cultured fibroblasts, and increases UIMC1 (RAP80) expression in blood and ovary. Simultaneously, the G allele decreases expression of ZNF346-IT1, an intronic transcript within ZNF346.

FGFR4 upregulation is biologically plausible as a fibroid risk mechanism. FGFR4 signaling promotes smooth muscle cell proliferation and survival — the same cellular program that drives leiomyoma growth. Studies in uterine leiomyosarcoma cells (smooth muscle tumor cells) show that FGFR4 inhibits apoptosis via the MST1/LATS1/GABP pathway, and elevated FGFR4 correlates with increased tumor aggressiveness. For the benign smooth muscle cells of the myometrium, excess FGFR4-driven proliferative signaling could lower the threshold for nodule formation.

The G allele also creates binding sites for 45 transcription factors, altering regulation of JAK-STAT signaling and vascular endothelial growth factor (VEGF) production⁴⁴ altering regulation of JAK-STAT signaling and vascular endothelial growth factor (VEGF) production
Pathways relevant to fibroid vascularization and growth, which may explain the observed link between this locus and cardiovascular comorbidity in fibroid patients.

The primary association was established in Välimäki et al. eLife 2018⁵⁵ Välimäki et al. eLife 2018
PMID 30226466, which analyzed 15,453 cases and 392,628 controls, identifying 22 genome-wide significant loci. The rs2456181 G allele showed OR 1.07 (p=6.3×10⁻⁹) — a small per-allele effect that is characteristic of common variant architecture. The study found that fibroid predisposition genes clustered into two pathways: genome stability (TERT, TERC, TP53, ATM) and genitourinary development (WNT4, WT1, ESR1, GREB1, FOXO1, MED12). The chromosome 5q35.2 locus did not fit cleanly into either category, suggesting it represents a distinct biological contribution.

A 2024 replication study⁶⁶ 2024 replication study
PMID 39736018, n=737 fibroid cases and 451 controls examined rs2456181 alongside six other GWAS loci and found it appeared in multiple significant gene-gene interaction models, particularly in combination with rs547025 (SIRT3) and rs10929757 (GREB1). A 2025 pilot study on fibroid-hypertension comorbidity⁷⁷ 2025 pilot study on fibroid-hypertension comorbidity
PMID 41504118 confirmed rs2456181's central role in epistatic networks — it appeared in five of seven most significant interaction models, with the G allele influencing JAK-STAT signaling and VEGF production pathways relevant to both fibroids and vascular disease.

Notably, the G allele frequency is substantially higher in women of African ancestry (~86%) compared to Europeans (~40%), consistent with the well-documented higher fibroid burden in Black women. However, population differences in fibroid prevalence and severity are multifactorial; social, environmental, and hormonal factors also contribute substantially.

Because each copy of the G allele adds only a modest increase in absolute risk (OR ~1.07), rs2456181 is not a clinically diagnostic variant on its own. Its value is in the context of a polygenic risk picture and in motivating proactive surveillance. Women who carry one or two G alleles have a modestly elevated lifetime probability of developing symptomatic fibroids and should be aware of the hallmark symptoms — heavy menstrual bleeding, pelvic pressure or pain, frequent urination, and back or leg pain — which are often normalized or attributed to other causes. Transvaginal ultrasound is the first-line detection method and is appropriate whenever symptoms are present.

Early detection of fibroids while they are small preserves the widest range of treatment options, from watchful waiting and medical management to uterine-sparing procedures like myomectomy or uterine artery embolization, rather than hysterectomy.

rs10929757 (GREB1): The GREB1 locus — a growth response gene regulated by estrogen — showed the most pronounced synergistic interaction with rs2456181 in gene-gene interaction analyses of uterine fibroid risk and hypertension comorbidity. GREB1 mediates estrogen-driven cell proliferation, suggesting that the FGFR4-upregulating effect of the G allele and estrogen-driven signaling through GREB1 may converge on the same pro-proliferative outcome in uterine smooth muscle.

rs58415480 (ESR1): The estrogen receptor alpha locus is the strongest individual GWAS signal for fibroids (OR 1.18). Together, ESR1 variants and rs2456181 place women carrying risk alleles at both loci at compounded risk, since estrogen receptor signaling is a primary driver of fibroid growth and FGFR4 amplifies the downstream proliferative response.

Polycystic ovary syndrome affects 5–15% of women of reproductive age and is the leading cause of anovulatory infertility worldwide. One of its defining features is hyperandrogenism¹¹ hyperandrogenism
excess androgen production, typically from ovarian theca cells, causing irregular periods, hirsutism, and impaired follicle maturation. A landmark 2011 genome-wide association study identified a cluster of variants in the DENND1A gene at chromosome 9q33.3 as among the first confirmed PCOS susceptibility loci — with rs2479106 carrying an odds ratio of 1.34 (P=8.12×10⁻¹⁹) in over 10,000 Han Chinese women. Subsequent functional work has revealed why this locus matters: DENND1A directly controls the theca cell machinery that produces androgens.

The Mechanism

DENND1A encodes DENN domain-containing protein 1A²² DENN domain-containing protein 1A
a guanine nucleotide exchange factor involved in endosomal trafficking and membrane receptor recycling. The protein has an alternatively spliced isoform, DENND1A.V2, that is markedly overexpressed in the theca cells of women with PCOS. When researchers forced expression of DENND1A.V2 in normal theca cells, the cells acquired a PCOS-like phenotype: they upregulated CYP17A1³³ CYP17A1
steroid-17α-hydroxylase/17,20 lyase, the rate-limiting enzyme in androgen biosynthesis and CYP11A1 (cholesterol side-chain cleavage enzyme), producing excess androgens and progestins. Conversely, knocking out DENND1A.V2 reduced these enzymes and suppressed androgen output.

The rs2479106 variant sits in an intron of the DENND1A gene, spanning a region containing at least 38 candidate regulatory elements between introns 2 and 6⁴⁴ at least 38 candidate regulatory elements between introns 2 and 6
identified by ATAC-seq and ENCODE enhancer overlap in a 2024/2025 study. Epigenetic activation of these intronic enhancers using dCas9-P300 produced 1.7–3.2-fold increases in testosterone in adrenal cell models. The rs2479106 locus thus marks a region of the genome that regulates how much DENND1A is expressed in steroidogenic cells — and consequently how much androgen those cells produce.

The Evidence

The original discovery was made in a staged GWAS by Chen et al. 2011 in Nature Genetics⁵⁵ Chen et al. 2011 in Nature Genetics
discovery cohort: 744 PCOS cases/895 controls; two replication cohorts totaling 3,338 PCOS cases/5,792 controls; all Han Chinese. The G allele at rs2479106 conferred an odds ratio of 1.34 at a combined P-value of 8.12×10⁻¹⁹ — statistical confidence well beyond genome-wide significance.

A 2013 genotype-phenotype study of over 2,000 Han Chinese PCOS women found that carriers of the G allele (GG+AG genotype) had significantly elevated serum insulin levels 2 hours after a 75g oral glucose challenge⁶⁶ significantly elevated serum insulin levels 2 hours after a 75g oral glucose challenge
P=0.02, dominant model, suggesting impaired post-load insulin clearance or early insulin secretory dysfunction. A 2020 follow-up in 2,082 PCOS women refined this: the AA genotype (no G alleles) was actually associated with a higher rate of insulin resistance (53.6% vs 48.3%; OR 0.80 for GG+AG, P=0.036 after age/BMI adjustment), though this association disappeared when subjects with a family history of diabetes were excluded — suggesting complex confounding.

Meta-analyses confirm population-specific effects. Gao et al. 2016 (8 studies, 8,185 cases/28,675 controls)⁷⁷ Gao et al. 2016 (8 studies, 8,185 cases/28,675 controls) found a significant association in Asian populations (OR 1.32, 95% CI 1.25–1.39) but not in European populations (OR 1.01). Similarly, a 2012 replication study in Caucasian European cohorts (1,144 cases/17,635 controls) found OR 1.05 (P=0.45) for rs2479106, while the neighboring SNP rs10818854 replicated strongly with P=9.8×10⁻⁸. This suggests rs2479106 is a tag SNP that tracks the causal variant in Asian populations through linkage disequilibrium, but that LD pattern differs across ancestries.

A 2023 meta-analysis by Larsen et al. (10 studies, 3,627 cases/20,325 controls)⁸⁸ Larsen et al. (10 studies, 3,627 cases/20,325 controls)
including subgroup analyses by ancestry and genetic model found the Asian subgroup recessive model showed OR 1.84 (P=0.006), and the overall dominant model approached significance at OR 1.31 (P=0.05).

Separately, a 2025 Nature Communications study from Mount Sinai and Duke University⁹⁹ a 2025 Nature Communications study from Mount Sinai and Duke University
using ATAC-seq, allele-specific reporter assays, and dCas9-P300 epigenetic editing in human PCOS theca cell models identified 4 regulatory variants in the DENND1A locus with allele-specific activity, providing the first direct molecular evidence that inherited variants in this region can dysregulate DENND1A expression and drive testosterone overproduction.

Practical Actions

For women carrying the G allele — particularly those of East or Southeast Asian ancestry where this variant has the strongest population-level effect — rs2479106 adds to the evidence base for earlier reproductive endocrinology evaluation if PCOS symptoms are present. Specific monitoring for androgen excess (total and free testosterone, DHEAS, androstenedione) and post-load insulin dysregulation (2-h glucose tolerance test) is warranted, as these are the phenotypic features most consistently associated with G-allele carriage in published cohorts.

PCOS management strategies that specifically address androgen-driven ovulatory dysfunction include inositol supplementation (myo-inositol reduces androgens and improves ovulatory function through insulin-sensitizing pathways) and anti-androgen monitoring at reproductive transitions (puberty, pregnancy planning, perimenopause).

Interactions

rs10818854 and rs10986105 (DENND1A): These two neighboring DENND1A variants show stronger and more consistent PCOS association in European populations (OR 1.36 and 1.39 respectively in meta-analyses, P<0.001 in European cohorts). rs10818854 and rs10986105 are in high LD with each other (r²>0.65) but not strongly with rs2479106. The three variants capture different aspects of risk in different ancestral LD structures.

rs6166 (FSHR N680S): The FSH receptor sensitivity variant interacts with PCOS susceptibility at the ovarian level. Women with PCOS-associated genotypes at DENND1A (excess androgen production) and low FSH receptor sensitivity (FSHR GG) may face a double challenge: impaired follicle development from reduced FSH response AND hyperandrogenic suppression of folliculogenesis. Combined profiling of DENND1A + FSHR may better characterize ovarian response to stimulation in a PCOS context. This is a proposed compound interaction — no published clinical trial has formally tested this combination.

rs13405728 (LHCGR): Another PCOS GWAS locus, the LH/hCG receptor. Elevated LH in PCOS drives theca cell androgen production through LHCGR; carriers of risk alleles at both DENND1A and LHCGR may have a compounding androgenic phenotype. Published data from the Chen 2011 GWAS identified both loci simultaneously, but compound effects of carrying risk alleles at both have not been quantified in published studies.

Psoriasis is one of the most common chronic autoimmune skin diseases, driven by aberrant activation of CD8+ T cells¹¹ aberrant activation of CD8+ T cells
CD8+ T cells are cytotoxic lymphocytes that recognize short peptides presented by HLA class I molecules on the surface of target cells against skin melanocytes. The key to understanding this SNP lies inside the endoplasmic reticulum (ER) of every cell. Before a peptide can be displayed on the cell surface by an HLA class I molecule, it must first be trimmed to the right length — typically 8-10 amino acids. ERAP1 (Endoplasmic Reticulum Aminopeptidase 1)²² ERAP1 (Endoplasmic Reticulum Aminopeptidase 1)
an enzyme that successively clips amino acids from the N-terminus of peptides, sculpting them to optimal length for MHC class I binding is the enzyme responsible for this trimming step. The rs27524 variant alters how much ERAP1 is produced, and in individuals who also carry HLA-C*06:02, this creates a precise mechanistic path to psoriasis.

The Mechanism

rs27524 is an intronic variant that functions as an expression quantitative trait locus (eQTL)³³ expression quantitative trait locus (eQTL)
a genetic variant that controls how much of a nearby gene's mRNA and protein are produced, rather than changing the protein sequence itself. The A (risk) allele is associated with higher ERAP1 expression and, inversely, lower ERAP2 expression, compared to the G allele. More ERAP1 activity means more aggressive peptide trimming in the ER.

For most people, this has little consequence. But in individuals who carry the HLA-C*06:02 allele, the story changes dramatically. HLA-C*06:02 is the MHC class I allele most strongly associated with psoriasis. It preferentially presents short peptides derived from melanocyte proteins — including the autoantigen ADAMTSL5⁴⁴ ADAMTSL5
a glycoprotein expressed by melanocytes that becomes a self-antigen in psoriasis when presented by HLA-C*06:02. The psoriasis risk ERAP1 haplotype (tagged by the A allele at rs27524) trims the 11-amino acid ADAMTSL5 precursor into a 9-10 amino acid peptide with high efficiency, generating a higher surface density of ADAMTSL5/HLA-C*06:02 complexes⁵⁵ higher surface density of ADAMTSL5/HLA-C*06:02 complexes
more self-peptide displayed per cell on melanocytes. This heightened display activates autoreactive CD8+ T cells that migrate to the skin and drive psoriatic inflammation.

The protective ERAP1 haplotype (G allele) trims the same precursor less efficiently, resulting in fewer functional autoantigen/HLA-C*06:02 complexes and reduced T-cell activation — even in HLA-C*06:02 carriers.

The Evidence

The association between rs27524 and psoriasis was first identified in a landmark 2010 GWAS by the Genetic Analysis of Psoriasis Consortium⁶⁶ landmark 2010 GWAS by the Genetic Analysis of Psoriasis Consortium
2,622 psoriasis cases vs 5,667 controls analyzed for 594,224 SNPs, with replication in 9,079 European samples. This study was notable for demonstrating the first genome-wide significant epistatic interaction between two GWAS loci: the ERAP1 rs27524 effect was only detectable in individuals carrying the HLA-C risk allele rs10484554 (a tag for HLA-C*06:02), with a combined interaction P-value of 6.95×10⁻⁶. In HLA-C*06:02 carriers, the odds ratio for rs27524 rises to approximately 1.43 (95% CI: 1.21-1.69); in non-carriers, no significant association is observed. Homozygosity for risk alleles at both loci substantially increases psoriasis odds compared to the most protective two-locus genotype, reflecting the strong epistatic interaction between ERAP1 and HLA-C.

A meta-analysis of 13 studies⁷⁷ meta-analysis of 13 studies
systematic review and meta-analysis by Zavattaro et al., combining 3,656 psoriasis cases and 3,982 controls across European and Asian populations confirmed the overall association (OR=1.18, 95% CI: 1.08-1.29, p<0.001), with consistent results in both Caucasian and Asian populations.

The functional mechanism was elucidated in 2021⁸⁸ functional mechanism was elucidated in 2021
In vitro peptide trimming assays and CD8+ T-cell activation assays using primary melanocytes and psoriatic T-cell lines: the risk ERAP1 haplotype generates the ADAMTSL5 autoantigen at substantially higher levels than the protective haplotype, and this quantitative difference directly correlates with CD8+ T-cell activation threshold.

The effect shows age-dependent nuance⁹⁹ age-dependent nuance
ERAP1 association was confined to individuals with disease onset between ages 10-20 (OR=1.59, 95% CI: 1.28-1.98); absent in cases with onset under 10 years and not detected in other age groups; within this onset-age-10-20 subgroup specifically, ERAP1 effects appeared independent of HLA-C*06:02 status in that analysis, suggesting that hormonal changes at puberty may interact with the ERAP1 peptide-trimming pathway to influence disease expression timing. This age-subgroup finding does not negate the overall genome-wide significant epistatic interaction between ERAP1 and HLA-C*06:02 from Strange et al. 2010 across the full cohort, which remains the primary framing for this SNP's clinical relevance.

Practical Implications

If you carry one or two copies of the A allele, your ERAP1 enzyme is expressed at higher levels and trims ER peptides more aggressively. This has two main consequences. First, it shifts the peptide repertoire displayed by your HLA class I molecules — potentially altering how your immune system perceives various self-proteins. Second, if you also carry HLA-C*06:02, the combined effect substantially elevates your lifetime risk for plaque psoriasis.

Psoriasis is a chronic condition that alternates between flares and remission. It ranges from mild (a few patches) to severe (widespread plaques, nail involvement, joint disease in psoriatic arthritis). Early diagnosis and consistent management can prevent joint damage and long-term complications.

Environmental triggers for psoriasis flares include skin trauma (Koebner phenomenon), streptococcal throat infections, certain medications (lithium, beta-blockers, NSAIDs, antimalarials), and rapid withdrawal of corticosteroids. Knowing your genetic risk profile allows you to watch for early signs and seek dermatological assessment promptly if characteristic plaques develop.

Interactions

ERAP1 rs27524 × HLA-C*06:02 (rs12191877): Epistasis

The most clinically relevant interaction for rs27524 involves HLA-C*06:02. The rs27524 A allele confers modest unconditional psoriasis risk (OR 1.18 in meta-analysis). The 2010 Strange et al. GWAS¹⁰¹⁰ GWAS
2,622 psoriasis cases vs. 5,667 controls; ERAP1 effect confined to HLA-C risk-allele carriers in this discovery cohort found that ERAP1 effects were confined to HLA-C*06:02 carriers (OR ~1.43 in carriers vs. no significant effect in non-carriers; combined epistasis P=6.95×10⁻⁶), which is mechanistically explained by ERAP1 trimming peptides that are then loaded onto HLA-C*06:02 for presentation. However, a subsequent age-stratified analysis (Lysell et al. 2012¹¹¹¹ Lysell et al. 2012
ERAP1 SNPs rs26653, rs30187, and rs27524 analyzed across age-at-onset groups; ERAP1 association confined to onset ages 10-20, OR 1.59, and found to be independent of HLA-C*06:02 status in contrast to the earlier epistasis model) found that the ERAP1 association in individuals with psoriasis onset between ages 10 and 20 was independent of HLA-C*06:02 status, suggesting the epistasis may be age-specific or population-specific rather than universal. The mechanistic model — ERAP1 trimming peptides for HLA-C*06:02 presentation — remains well-supported by functional data; the degree to which the clinical genetic effect is obligatorily HLA-C*06:02-dependent is not fully resolved across all age and population subgroups.

This interaction is a candidate for compound action documentation. The relevant genotypes are: - rs27524 AA or AG (ERAP1 risk allele present) combined with - rs12191877 CT or TT (HLA-C*06:02 tag SNP risk allele present)

The combined recommendation in this context would center on heightened psoriasis surveillance, early dermatological assessment, awareness of Koebner triggers, and discussion of prophylactic streptococcal management given the strong strep-to-flare link in early-onset psoriasis.

ERAP1 also interacts epistatically with HLA-B27 in ankylosing spondylitis¹²¹² HLA-B27 in ankylosing spondylitis
ERAP1 variants affect AS risk only in HLA-B27 positive individuals, paralleling the psoriasis/HLA-C*06:02 interaction, highlighting a general principle that ERAP1's clinical significance is always conditioned on the specific HLA class I allele background.

Every time a blood vessel is damaged, von Willebrand factor (VWF)¹¹ von Willebrand factor (VWF)
a large adhesive protein stored in endothelial cells and platelets that uncoils upon vascular injury to capture circulating platelets floods the injury site, unfurling into enormous multimers that recruit platelets to form the initial clot. Left unchecked, these ultra-large VWF multimers would persist in the circulation and trigger dangerous spontaneous platelet aggregation. The enzyme that prevents this is ADAMTS13²² ADAMTS13
ADAM metallopeptidase with thrombospondin type 1 motif 13, encoded by ADAMTS13 on chromosome 9q34.2 — a VWF-specific protease produced mainly in the liver and released into the bloodstream, where it continuously trims VWF multimers to safe sizes. The balance between VWF production and ADAMTS13-mediated cleavage is a critical dial for thrombotic risk. rs28673647 is an intronic ADAMTS13 variant that shifts this dial.

The Mechanism

rs28673647 sits in an intron of ADAMTS13 and does not alter the protein sequence. Its effect is regulatory: by modifying gene expression, splicing efficiency, or mRNA stability within the ADAMTS13 locus on 9q34.2, the G allele increases the amount of functional ADAMTS13 enzyme circulating in plasma. The A allele produces the lower, population-baseline ADAMTS13 level. Because each G allele adds approximately 6.7% to plasma concentration, the three genotypes form a gradient: AA (lowest) < AG (intermediate) < GG (highest).

When ADAMTS13 activity is insufficient relative to VWF release — whether because of low ADAMTS13 protein, inhibitory antibodies (as in immune TTP), or acute-phase consumption — ultra-large VWF multimers³³ ultra-large VWF multimers
multimers that are far more adhesive than processed VWF and bind platelet GPIbα with very high affinity under shear stress accumulate in the microvasculature. These hyper-reactive multimers anchor platelets indiscriminately, forming platelet-rich thrombi in small vessels. The clinical spectrum runs from subclinical thrombotic propensity at mild reductions, through elevated CHD and DVT risk at moderate deficiency, to full thrombotic thrombocytopenic purpura (TTP) when activity falls below 10%.

The Evidence

The genetic association was established by Ma et al. 2017⁴⁴ Ma et al. 2017
Ma Q, Jacobi PM, Emmer BT et al. Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels. Blood Adv. 2017;1(18):1375-1388. in a GWAS of healthy individuals. The rs28673647 G allele was the top intronic signal, with a β of +6.7% for plasma ADAMTS13 concentration and a p-value of 1.3×10⁻⁵² — one of the most significant genetic associations for any plasma enzyme level. Common variants across the ADAMTS13 locus collectively explained 20% of the variance in plasma ADAMTS13 levels. The same study found that tobacco smoking independently reduced plasma ADAMTS13 by a clinically meaningful amount — a modifiable environmental factor acting on the same pathway as the A allele.

The downstream clinical consequences of low ADAMTS13 were quantified in the Rotterdam Study⁵⁵ Rotterdam Study
Sonneveld MA et al. Low ADAMTS-13 activity and the risk of coronary heart disease. J Thromb Haemost. 2016;14(11):2114-2120. — a prospective cohort of 5,688 participants aged 55+ with 456 incident CHD events over 9.7 years. ADAMTS13 activity in the lowest quartile conferred a hazard ratio of 1.42 (95% CI 1.07–1.89) for CHD compared to the highest quartile, independent of VWF levels and traditional cardiovascular risk factors. For venous thrombosis, Pagliari et al. 2021⁶⁶ Pagliari et al. 2021
Pagliari MT et al. ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis. Thromb Res. 2021;198:92-98. showed that ADAMTS13 activity below the first quartile (≤86%) gave a 1.6-fold increased DVT risk (OR 1.6, 95% CI 1.05–2.55) in 657 Italian subjects; the combination of low ADAMTS13 with high VWF amplified DVT risk 15-fold (95% CI 7.80–33.80).

In stable coronary artery disease, an elevated vWF/ADAMTS13 antigen ratio — reflecting the same imbalance — predicted an adjusted OR of 1.86 (95% CI 1.45–2.82) for MI, stroke, or death at two-year follow-up in 999 aspirin-treated patients (Warlo et al. 2017)⁷⁷ (Warlo et al. 2017).

Practical Actions

For AA homozygotes — the genotype with the lowest ADAMTS13 levels — the most actionable intervention is eliminating tobacco exposure. Smoking is the largest modifiable environmental determinant of ADAMTS13 levels (Ma et al. 2017), and for AA individuals there is no genetic buffer from a G allele. Measuring the VWF:ADAMTS13 ratio directly quantifies the ADAMTS13-VWF balance and is clinically useful when additional thrombotic risk factors are present.

For AG and GG carriers, the same smoking-avoidance principle applies: the environmental ADAMTS13-lowering effect of tobacco is independent of genotype and can neutralize the genetic advantage from G alleles.

Interactions

ADAMTS13 does not act in isolation. The VWF-cleaving axis interacts directly with VWF levels, which are determined partly by rs1063856 (VWF gene variant) and ABO blood group (O blood group is associated with ~25% lower VWF). An AA individual with high VWF levels — from a VWF-increasing variant, non-O blood group, or inflammatory state — faces a particularly adverse ADAMTS13:VWF ratio. The 15-fold DVT risk observed with combined low ADAMTS13 + high VWF in Pagliari et al. 2021 illustrates this interaction's clinical magnitude. rs3739893 is a second major independent ADAMTS13 signal (β = −22.3%, p = 1.2×10⁻³⁰) with a much larger negative effect on ADAMTS13 levels; the combination of rs3739893 risk genotype with AA at rs28673647 would substantially compound the ADAMTS13-lowering effect.

3β-hydroxysteroid dehydrogenase type 2¹¹ 3β-hydroxysteroid dehydrogenase type 2
encoded by HSD3B2; the rate-limiting enzyme for converting Δ5-precursors (pregnenolone, 17-OH-pregnenolone, DHEA) into the active Δ4-steroids (progesterone, 17-OH-progesterone, androstenedione) is indispensable for the biosynthesis of all major steroid hormones — mineralocorticoids (aldosterone), glucocorticoids (cortisol), and sex steroids (testosterone, estrogens). The enzyme is expressed in both the adrenal cortex and the gonads. Without it, the body cannot complete the conversion from cholesterol-derived precursors to functional steroids in either tissue.

The rs28934880 variant introduces a C-to-A transversion in exon 1 of HSD3B2, changing codon 10 from GCA (alanine) to GAA (glutamic acid). This single amino acid substitution — p.Ala10Glu — was first characterized in two French-Canadian families presenting with severe salt-wasting congenital adrenal hyperplasia (CAH), and evidence of a shared ancestral haplotype spanning 3.3 cM around the locus points to a founder event in that population. The variant is exceptionally rare globally (gnomAD genomes: 1 observation in 149,092 alleles).

The Mechanism

Alanine at position 10 is highly conserved across the entire 3βHSD gene family in vertebrates²² Alanine at position 10 is highly conserved across the entire 3βHSD gene family in vertebrates
Conservation at this site implies structural or catalytic importance across species. The residue sits in the enzyme's NAD-binding domain — the cofactor-binding pocket that the enzyme requires to carry out oxidation and isomerization of Δ5-steroids. Replacing the small, non-polar alanine with a bulkier, negatively charged glutamic acid at this site is expected to disrupt the geometry of the NAD-binding pocket and destabilize the protein's tertiary structure.

Functional studies in transfected Ad293 cells confirmed this prediction: the Ala10Glu mutant enzyme exhibited no detectable 3β-HSD activity³³ the Ala10Glu mutant enzyme exhibited no detectable 3β-HSD activity
Intact-cell transfection assays quantify the enzyme's ability to convert substrate in a cellular environment; zero detectable activity means essentially no functional enzyme is produced or retained. This is a complete loss-of-function variant. When both copies of HSD3B2 carry this (or another severe) mutation, the adrenal cortex and gonads cannot produce glucocorticoids, mineralocorticoids, or sex steroids from their Δ5-steroid precursors. The consequent accumulation of DHEA and 17-OH-pregnenolone alongside deficiency of cortisol and aldosterone defines the biochemical signature of the disorder.

Because HSD3B1 (the type 1 isoenzyme, expressed in placenta and peripheral tissues) is encoded by a different gene and is not affected, partial peripheral conversion of androgens can still occur via HSD3B1 — explaining why some affected individuals show partial masculinization during puberty despite adrenal/gonadal deficiency.

The Evidence

The index case characterization comes from Alos et al. 2000 (J Clin Endocrinol Metab 85:1968–74)⁴⁴ Alos et al. 2000 (J Clin Endocrinol Metab 85:1968–74)
A novel A10E homozygous mutation in HSD3B2 gene causing severe salt-wasting 3beta-hydroxysteroid dehydrogenase deficiency in 46,XX and 46,XY French-Canadians: evaluation of gonadal function after puberty. Two unrelated homozygous patients — one 46,XX, one 46,XY — both presented in infancy with salt-wasting CAH. The 46,XY patient achieved partial masculinization during puberty through peripheral HSD3B1 activity, but semen analysis at age 18.5 showed azoospermia; the 46,XX patient reached menarche and had progesterone secretion, demonstrating residual gonadal function via peripheral conversion.

A comprehensive 2019 review by Al Alawi, Nordenström and Falhammar (Endocrine 64:622–634)⁵⁵ Al Alawi, Nordenström and Falhammar (Endocrine 64:622–634)
Clinical perspectives in congenital adrenal hyperplasia due to 3β-hydroxysteroid dehydrogenase type 2 deficiency synthesized data from all published HSD3B2 cases. A critical point for carriers: "the hormonal profile cannot distinguish heterozygous carriers from normal people" — molecular genetic testing is required to identify carrier status. The review documents that over 40 HSD3B2 mutations have been characterized, with null mutations (frameshift, nonsense) invariably causing salt-wasting, while missense mutations with residual activity (~10%) are associated with non-salt-wasting phenotypes.

Mermejo et al. 2005 (J Clin Endocrinol Metab 90:1287–93)⁶⁶ Mermejo et al. 2005 (J Clin Endocrinol Metab 90:1287–93) established biochemical thresholds: ACTH-stimulated 17-OH-pregnenolone ≥201 nmol/L distinguishes genotype-confirmed HSD3B2-deficient patients from hormonal-only evaluations, helping reduce false-positive diagnoses. Importantly, their data showed heterozygous parents of affected children had intermediate but not clearly elevated hormone levels — again supporting that carriers do not have detectable clinical disease.

Male fertility in treated patients is not uniformly lost. Donadille et al. 2018 (Endocrine Connections 7:R255–R265)⁷⁷ Donadille et al. 2018 (Endocrine Connections 7:R255–R265) reported a 24-year-old male homozygote with a different HSD3B2 deletion who maintained sperm concentrations of 57.6 million/mL under replacement therapy — the first report of adequate spermatogenesis in a clinically confirmed case, suggesting that early diagnosis and steroid replacement may preserve fertility in some males.

Practical Actions

For heterozygous carriers (AC genotype), no clinical management is required — adrenal and gonadal steroid production is entirely normal with one functional gene copy. The clinical relevance is reproductive: each pregnancy with another carrier carries a 25% probability of an affected child. Informing a reproductive endocrinologist or genetic counselor before conception allows informed decisions.

For homozygous individuals (AA genotype), this is a medical condition requiring specialist management. Long-term glucocorticoid replacement (hydrocortisone 10–15 mg/m²/day, divided three times daily) suppresses excess Δ5-androgens and replaces cortisol. Salt-wasting forms additionally require mineralocorticoid replacement (fludrocortisone 0.1 mg/day with sodium supplementation in infancy). Androgen management is typically more challenging than in 21-hydroxylase deficiency. Fertility preservation counseling should be initiated early in adulthood.

Interactions

Compound heterozygosity — one Ala10Glu allele plus a second distinct HSD3B2 pathogenic variant — produces the same phenotypic spectrum as homozygosity for either single variant, since both copies of HSD3B2 are nonfunctional. The severity depends on the residual activity of the second allele: a missense mutation with ~10% activity combined with the Ala10Glu null allele may produce a milder non-salt-wasting phenotype. Full genotype characterization of both alleles is essential for prognosis.

Toll-like receptor 9 (TLR9)¹¹ Toll-like receptor 9 (TLR9)
TLR9 is an endosomal pattern recognition receptor that detects unmethylated CpG dinucleotide motifs — a molecular signature abundant in bacterial and viral DNA but rare in methylated mammalian genomic DNA is one of the body's most important early-warning sensors for microbial invasion. The rs352140 variant, located in exon 2 of the TLR9 gene at position 2848 of the coding sequence, is synonymous at the protein level — the amino acid sequence of TLR9 is unchanged. Yet despite producing an identical protein, this variant measurably alters TLR9 mRNA expression levels²² this variant measurably alters TLR9 mRNA expression levels
Multiple independent studies have shown that T allele carriers have higher TLR9 transcript levels in immune cells and placental tissue, making it a regulatory variant disguised as a silent mutation.

The T allele (described as the A allele in some older literature using gene-strand notation) is strikingly common — carried by roughly half of Europeans and about a third of East Asians and Africans. This high frequency makes rs352140 one of the most studied TLR9 polymorphisms, with over 129 publications examining its role across infections, autoimmune diseases, and cancer susceptibility.

The Mechanism

TLR9 resides inside endosomes — membrane-bound compartments where degraded microbial material is processed after phagocytosis. When bacterial or viral DNA containing unmethylated CpG sequences arrives in the endosome, TLR9 binds these motifs and triggers a signaling cascade through MyD88 and TRAF6³³ MyD88 and TRAF6
Key adaptor proteins in innate immune signaling that activates NF-κB and interferon regulatory factors (IRFs). The result is rapid production of pro-inflammatory cytokines (IL-6, TNF-α, IL-12) and type I interferons (IFN-α, IFN-β) — the first-line molecular alarm system for infections.

Although rs352140 does not change the TLR9 protein sequence, it appears to affect mRNA stability or splicing efficiency⁴⁴ it appears to affect mRNA stability or splicing efficiency
Synonymous variants can alter codon usage, mRNA secondary structure, and ribosome elongation speed, all of which affect protein output. T allele carriers show higher TLR9 expression, meaning their innate immune cells produce more TLR9 receptors and therefore mount amplified responses when CpG DNA is detected. This heightened sensitivity is a double-edged sword: more responsive to genuine pathogens, but also more prone to over-activation by self-DNA released during cell death — the proposed mechanism linking TLR9 to autoimmunity.

The Evidence

The clinical literature on rs352140 is extensive but heterogeneous, reflecting the variant's involvement in multiple biological contexts.

Placental inflammation and preterm birth: A study of 159 infants found that CT/TT genotype carriers had 3.8–4.2-fold higher odds of placental inflammation compared to CC homozygotes (OR 4.2, 95% CI 1.5–11.4, p=0.005)⁵⁵ A study of 159 infants found that CT/TT genotype carriers had 3.8–4.2-fold higher odds of placental inflammation compared to CC homozygotes (OR 4.2, 95% CI 1.5–11.4, p=0.005)
Association held after adjusting for confounders including gestational age and rupture of membranes. The maternal pattern of inflammation — suggesting maternal immune activation at the placenta — was 100% penetrant in preterm infants with CT/TT genotype. The proposed mechanism is enhanced TLR9 recognition of bacterial CpG motifs at the maternal-fetal interface, triggering excessive inflammatory responses.

Type 1 diabetes: In 1,513 Han Chinese participants, the T allele conferred significantly elevated T1D risk (OR=1.19, 95% CI 1.03–1.39, p=0.019), with the TT genotype showing stronger effect (OR=1.54, 95% CI 1.11–2.13, p=0.010)⁶⁶ In 1,513 Han Chinese participants, the T allele conferred significantly elevated T1D risk (OR=1.19, 95% CI 1.03–1.39, p=0.019), with the TT genotype showing stronger effect (OR=1.54, 95% CI 1.11–2.13, p=0.010)
Study from Central South University, published 2023. The proposed mechanism involves enhanced TLR9-mediated type I interferon production activating autoreactive T cells targeting pancreatic beta cells.

Cancer: A meta-analysis of 14,091 subjects found that TT genotype carriers had increased cancer risk in Caucasians (OR=1.40 in recessive model, 95% CI 1.02–1.92, p=0.039)⁷⁷ A meta-analysis of 14,091 subjects found that TT genotype carriers had increased cancer risk in Caucasians (OR=1.40 in recessive model, 95% CI 1.02–1.92, p=0.039)
Analysis covered bladder cancer, ALL, hepatocellular carcinoma, Hodgkin lymphoma, and breast cancer. A separate meta-analysis found a protective effect against breast cancer specifically in African Americans (GA vs GG: OR=0.77). These divergent findings across cancer types suggest the direction of risk depends on the specific tissue, immune microenvironment, and pathogen exposure history.

Behçet's disease: In 205 Iranian BD patients and 207 controls, CT and combined TT+CT genotypes were more frequent in healthy controls than patients (p=0.01), suggesting these genotypes protect against BD⁸⁸ In 205 Iranian BD patients and 207 controls, CT and combined TT+CT genotypes were more frequent in healthy controls than patients (p=0.01), suggesting these genotypes protect against BD
Effect strongest in females. This paradox — the same T allele that increases cancer and T1D risk appears protective against BD — illustrates how TLR9 variants have context-dependent effects depending on which immune pathways dominate in each disease.

Systemic lupus erythematosus: Individual studies have linked rs352140 to SLE susceptibility, lupus nephritis, and elevated anti-dsDNA antibodies (OR ~3.7 for TT/CT genotypes for immunologic disorders). However, a 2023 meta-analysis pooling genetic association studies found no statistically significant overall SLE association in any genetic model across Asian, European, or Latin American ancestry groups⁹⁹ a 2023 meta-analysis pooling genetic association studies found no statistically significant overall SLE association in any genetic model across Asian, European, or Latin American ancestry groups
PMID 37265090, suggesting the association may be population-specific or confounded by linkage disequilibrium with nearby causal variants.

Practical Implications

The T allele's signature is increased TLR9-mediated immune vigilance. For most people, this translates to a somewhat heightened innate immune tone — potentially beneficial for clearing infections but carrying modestly elevated risk for immune-mediated conditions. The evidence is clearest for placental inflammation and type 1 diabetes risk; the cancer associations require confirmation across additional populations and cancer types.

For individuals with CT or TT genotypes, the practical implications center on monitoring immune-mediated conditions (particularly autoimmune disorders, inflammatory states during pregnancy, and cancer screening), rather than lifestyle modifications that would alter the genetic effect. There are no known dietary or supplement interventions that specifically modulate TLR9 expression in clinically meaningful ways.

Interactions

The rs352140 variant is often studied alongside the TLR9 promoter variant [rs187084 (-1486T/C) | Located in the TLR9 gene promoter region, this variant also affects transcription factor binding and TLR9 expression], and these two SNPs are frequently inherited together as a haplotype. Combined haplotype analyses generally show stronger associations than either SNP alone, particularly for SLE and hepatitis susceptibility. The TLR9 pathway also intersects with [TLR2 (rs5743708) | TLR2 recognizes bacterial lipoproteins and peptidoglycan, a complementary pathway to TLR9's DNA sensing] and [TLR4 (rs4986790) | TLR4 detects bacterial LPS], such that individuals carrying risk variants in multiple toll-like receptors have altered innate immune profiles affecting susceptibility to diverse pathogens and inflammatory conditions.

Your body's ability to absorb dietary iron is governed by a small hormone called hepcidin¹¹ hepcidin
A 25-amino-acid peptide produced by the liver that acts as the master regulator of systemic iron levels. It binds and degrades ferroportin, the sole known cellular iron exporter, on gut enterocytes and macrophages, blocking iron absorption and iron recycling. Under normal conditions, when iron stores are low, hepcidin falls and the gut absorbs more iron. This feedback loop is maintained by matriptase-2²² matriptase-2
The protein product of TMPRSS6; a type II transmembrane serine protease expressed predominantly in the liver that cleaves membrane hemojuvelin, removing a critical activating signal for hepcidin transcription.

The rs387907018 variant (also called E522K, referring to the same amino acid change in different isoform numbering systems) is a missense mutation in TMPRSS6 that substitutes lysine for glutamic acid in the second LDL-receptor class A (LDLRA2) domain³³ second LDL-receptor class A (LDLRA2) domain
One of three LDLRA repeats in the extracellular region of matriptase-2; contains a conserved D/NXSDE calcium-binding motif essential for proper protein folding and cell-surface targeting. This is one of over 70 pathogenic TMPRSS6 variants; together they cause iron-refractory iron deficiency anemia⁴⁴ iron-refractory iron deficiency anemia
IRIDA — OMIM #206200. A rare autosomal recessive disorder characterised by hypochromic microcytic anemia that does not respond to oral iron supplementation because constitutively elevated hepcidin prevents gut iron absorption regardless of iron status (IRIDA).

The Mechanism

Matriptase-2 keeps hepcidin in check by cleaving membrane hemojuvelin⁵⁵ membrane hemojuvelin
A GPI-anchored protein that acts as a co-receptor for bone morphogenetic proteins (BMPs). When intact on the hepatocyte surface, it amplifies BMP-SMAD signalling to increase hepcidin transcription. Matriptase-2 removes it by proteolytic cleavage, blunting the hepcidin signal, a BMP co-receptor that potently stimulates hepcidin transcription. When matriptase-2 is functional, it cleaves membrane hemojuvelin in proportion to the body's iron needs, providing a tunable brake on hepcidin. When it is disabled, hemojuvelin accumulates on the hepatocyte surface and hepcidin is produced constitutively, even in the face of severe iron deficiency.

The E522K substitution sits in the conserved D/NXSDE calcium-binding motif of the LDLRA2 domain. Loss of this calcium coordination partially misfolds the extracellular region, causing the protein to be retained in the Golgi apparatus⁶⁶ retained in the Golgi apparatus
The cell's protein sorting and packaging station, located between the endoplasmic reticulum and the plasma membrane. Proteins retained there are not delivered to the cell surface and cannot carry out their membrane-bound functions rather than reaching the plasma membrane. Cell biology studies⁷⁷ Cell biology studies
Silvestri et al. Molecular mechanisms of the defective hepcidin inhibition in TMPRSS6 mutations associated with iron-refractory iron deficiency anemia. Blood, 2009 confirmed that E522K matriptase-2 shows absent autoactivation, absent hemojuvelin cleavage, and only partial hepcidin repression in transfection assays — despite retaining the physical ability to bind hemojuvelin.

The end result is a broken feedback loop: the gut cannot absorb dietary iron because hepcidin is always elevated, and oral iron supplements cannot overcome the block. This is why IRIDA is by definition refractory to oral iron.

The Evidence

TMPRSS6 was identified as the IRIDA gene by Finberg et al. in 2008⁸⁸ Finberg et al. in 2008
Finberg KE et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet, 2008, studying five multiplex kindreds and two sporadic cases with IRIDA unresponsive to oral iron. All affected individuals had biallelic loss-of-function TMPRSS6 mutations and inappropriately elevated urinary hepcidin despite severe iron deficiency and microcytic anemia.

The E522K variant specifically was characterised by Silvestri et al. in 2009⁹⁹ Silvestri et al. in 2009
Silvestri L et al. Molecular mechanisms of the defective hepcidin inhibition in TMPRSS6 mutations associated with iron-refractory iron deficiency anemia. Blood, 2009. The mutation was identified in compound heterozygosity (alongside D521N at the same LDLRA2 domain) in a patient with clinical IRIDA. Both variants caused Golgi retention of the protein and complete loss of hemojuvelin cleavage activity, while still allowing hemojuvelin binding — demonstrating that the LDLRA2 domain is required for cell surface localisation and catalytic activation but not for substrate recognition.

In gnomAD (v4 exomes), the T allele is observed in 40 out of 1,400,880 alleles (~2.9 per 100,000), confirming its classification as an ultra-rare pathogenic variant. No homozygotes have been observed in gnomAD, consistent with the rarity and clinical severity of biallelic TMPRSS6 loss.

Practical Implications

IRIDA is managed with parenteral iron¹⁰¹⁰ parenteral iron
Iron delivered intravenously, bypassing the gut entirely. Intravenous iron reaches macrophages directly; the subsequent rise in ferroportin expression partially overcomes hepcidin's block on iron release, restoring iron availability to erythroid progenitors rather than oral iron, since hepcidin elevation completely blocks intestinal absorption. Current expert guidance¹¹¹¹ expert guidance
Expert opinion-based treatment guidance for IRIDA in children and adults, 2025 recommends IV iron in smaller, frequent doses (maximum 500 mg elemental iron per session at two-week intervals) to avoid paradoxically raising hepcidin further. Treatment targets quality of life and a transferrin saturation of ~15% rather than normalisation of hemoglobin. Biallelic carriers typically present in childhood with severe microcytic anemia (MCV 45-65 fL) and transferrin saturation below 5%.

Heterozygous carriers of IRIDA-causing TMPRSS6 variants generally have normal iron parameters, though emerging evidence¹²¹² emerging evidence
Transferrin Saturation/Hepcidin Ratio study distinguishing monoallelic IRIDA from multi-causal IDA. Blood, 2022 shows that some monoallelic carriers have intermediate hepcidin dysregulation and can present with a milder IRIDA phenotype — particularly women, where menstrual iron losses add environmental pressure to the partial pathway impairment.

Interactions

The most clinically important interaction is between this variant and a second TMPRSS6 pathogenic allele. IRIDA requires biallelic loss of matriptase-2 function — compound heterozygosity (one E522K allele plus another pathogenic TMPRSS6 variant) produces full IRIDA just as homozygosity does. If a heterozygous carrier reproduces with another TMPRSS6 pathogenic variant carrier, there is a 25% chance per pregnancy of a child with IRIDA.

TMPRSS6 variants also interact indirectly with the common TMPRSS6 rs855791 (Ala736Val) polymorphism, which modulates the same hepcidin regulatory pathway. Carrying an IRIDA-causing allele (rs387907018) alongside the iron-lowering haplotype of rs855791 could theoretically worsen iron status in heterozygous carriers, although direct evidence for this specific combination is not published.

HFE variants rs1800562 (C282Y) and rs1799945 (H63D) affect the same BMP-hepcidin axis from the opposite direction — HFE mutations reduce hepcidin and cause iron overload, while TMPRSS6 loss-of-function variants constitutively elevate hepcidin and cause iron deficiency. Compound heterozygosity across these genes (one HFE and one TMPRSS6 allele) is not well-studied but could produce offsetting effects on iron status.

Endothelial nitric oxide synthase (eNOS), encoded by NOS3, is the enzyme that keeps blood vessels relaxed and healthy. By producing nitric oxide (NO) in the inner lining of blood vessels, eNOS lowers blood pressure, prevents clot formation, and dampens inflammation. rs3918226 sits in the promoter region of NOS3 — the stretch of DNA that acts as a volume control for how much enzyme the cell makes.

The Mechanism

The rs3918226 T allele disrupts a binding site for ETS transcription factors¹¹ ETS transcription factors
E-twenty six (ETS) proteins are a family of transcription factors that activate gene expression by binding specific DNA sequences in promoters in the NOS3 promoter. When the T allele is present, ETS factors bind less effectively, and the cell transcribes less NOS3 mRNA. Cell experiments confirm that the T allele reduces eNOS promoter activity by 20–40% compared to the reference C allele. Less eNOS means less nitric oxide, which means blood vessels are less able to relax on demand — a direct path to higher blood pressure and endothelial dysfunction.

This variant is distinct from two other well-studied NOS3 polymorphisms: rs2070744 (T-786C, a second promoter variant) and rs1799983 (Glu298Asp, a missense variant affecting enzyme stability). All three reduce NO bioavailability through different mechanisms and can interact when present together.

The Evidence

A genome-wide association study²² genome-wide association study
Salvi E et al. Genomewide association study identifies novel essential hypertension susceptibility locus. Hypertension, 2012 combining 21,714 subjects found rs3918226 to be among the strongest genetic predictors of essential hypertension identified to date: OR 1.34 (95% CI 1.25–1.44; P = 1.032 × 10⁻¹⁴), with each T allele adding approximately 1.9 mmHg systolic and 1.4 mmHg diastolic blood pressure on average.

A follow-up prospective study³³ prospective study
Salvi E et al. Target sequencing, cell experiments, and a population study establish eNOS gene as hypertension susceptibility gene. Hypertension, 2013 in 2,722 European adults followed for 7.6 years showed that TT homozygotes experienced a blood pressure rise of 9.7/6.8 mmHg (systolic/diastolic) compared to 3.8/1.9 mmHg in C-allele carriers. Among the 2,013 who were normotensive at baseline, TT homozygosity conferred a hazard ratio of 2.04 (95% CI 1.24–3.37; P = 0.005) for developing hypertension — a doubling of risk. The T allele is rare globally (5–8% frequency) but enriched in European populations (~8%), where the hypertension burden is also high.

Practical Actions

Because this variant reduces eNOS transcription rather than enzyme function, approaches that supply nitric oxide through alternative pathways are particularly relevant. Dietary nitrates from beetroot, spinach, arugula, and celery are converted by oral bacteria to nitrite, and then to NO in the acidic environment of the stomach and blood — entirely bypassing eNOS. This pathway has been shown to lower blood pressure by 4–10 mmHg in clinical trials of high-nitrate diets.

Antioxidant support matters because reduced eNOS activity can shift the enzyme toward producing superoxide (oxidative stress) rather than NO — a state called eNOS uncoupling. Vitamin C helps recycle the eNOS cofactor BH4, keeping what enzyme is present in its NO-producing mode.

Blood pressure monitoring is actionable: a sustained reading above 130/80 mmHg warrants discussion with a clinician about pharmacological support. CT/TT carriers on antihypertensive medications may respond differently to drug classes that modulate NO signaling, as shown by pharmacogenomic studies of this locus.

Interactions

rs3918226 can interact with the nearby NOS3 promoter variant rs2070744 (T-786C) and the coding variant rs1799983 (Glu298Asp) to produce compounded reductions in NO bioavailability. Carriers of the T allele at rs3918226 who also carry the C allele at rs2070744 and/or the T allele at rs1799983 face additive risk from multiple independent impairments to eNOS expression and enzyme stability. These interactions are described in the Salvi 2013 study and in haplotype analyses of NOS3 variants in migraine and cardiovascular disease cohorts.